Navigation

🏠 Home 📰 Latest News 🌍 World 🇮🇳 India 💼 Business 💻 Technology ⚽ Sports 🎬 Entertainment 🏥 Health
Biggest News Aggregation in the World
📰 Underdiagnosed Form News

Underdiagnosed Form News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Underdiagnosed Form. Real-time updates on events, politics, business and more.

Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathy

February 8, 2024
CARLSBAD, Calif., Feb. 8, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration has granted Fast Track designation to Ionis and AstraZenecas...
Sarah Walters Eugene Schneider Ionis Pharmaceuticals Drug Administration Ionis Pharmaceuticals Inc Columbia University Irving Medical Center
Source: marketscreener.com

AstraZeneca : Wainua (eplontersen) granted first-ever regulatory approval in the US for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis - Form 6-K -December 22, 2023 at 06:21 am EST

December 22, 2023
A7568x FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or...
United Kingdom United States Ioni Wainua Isabelle Lousada Michaelj Polydefkis Adrian Kemp
Source: marketscreener.com

NEURO-TTRansform Phase III results presented at AAN showed eplontersen demonstrated consistent and sustained improvement in all measures of disease and quality of life through 66 weeks

April 24, 2023
Eplontersen halted neuropathy disease progression and improved neuropathy impairment and quality of life ... | June 18, 2023
United States United Kingdom American Academy Of Neurology Columbia University Irving Medical Center Drug Administration Ionis Pharmaceuticals
Source: marketscreener.com

Eplontersen demonstrated sustained benefit in Phase III trial for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) through 66 weeks

March 27, 2023
Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy showed eplontersen met its co-primary endpoints... | March 27, 2023
United Kingdom United States Eugene Schneider Sami Khella Penn Presbyterian Medical Center Drug Administration
Source: marketscreener.com

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science